Jorgen Winroth - Swedish Orphan Insider

Swedish Orphan Biovitrum AB -- USA Stock  

USD 14.72  0.0005  0.0034%

Head of Investor Relations and VP

Mr. Jorgen Winroth was appointed Vice President, Head of Investor Relations at Swedish Orphan Biovitrum AB, effective as of November 16, 2012. He has served as Director, Investor Relations for AstraZeneca North America for the past sixteen years. He has also served as Consultant providing strategic Investor Relations services to a number of Scandinavian companies including Hafslund Nycomed AS, AB SKF, Huhtamaki Oy. He also served as Vice President, Investor Relations at Pharmacia.
  VP Since 2012      
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 5.92 % which means that it generated profit of $5.92 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.34 % meaning that it generated $11.34 on every $100 dollars invested by stockholders.
The company has accumulated 60.4 M in total debt with debt to equity ratio (D/E) of 8.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.69 which is within standard range for the sector.

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.

Did you try this?

Run Coins and Tokens Correlation Now
   

Coins and Tokens Correlation

Utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges
Hide  View All  NextLaunch Coins and Tokens Correlation
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Swedish Orphan Biovitrum AB to your portfolio

Top Management

Swedish Orphan Biovi Leadership Team
Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance

Swedish Orphan Performance Indicators